(Q45985296)

English

Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.

scientific article published on 2 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Parkinson's disease

1 reference

based on heuristic

inferred from title

author name string

Carol Addy

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Chris Assaid

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

David Hreniuk

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Mark Stroh

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Yang Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

W Joseph Herring

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Aaron Ellenbogen

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

H A Jinnah

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Louis Kirby

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Mark T Leibowitz

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

R Malcolm Stewart

11

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Daniel Tarsy

12

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

James Tetrud

13

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

S Aubrey Stoch

14

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Keith Gottesdiener

15

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

John Wagner

16

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

publication date

2 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

49

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

856-864

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Parkinson's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Prevalence of parkinsonian signs and associated mortality in a community population of older people.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Ageing and Parkinson's disease: substantia nigra regional selectivity

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Motor fluctuations and dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Levodopa strengths and weaknesses

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Excitotoxicity and the NMDA receptor--still lethal after eight years

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Marmoset monkey models of Parkinson's disease: which model, when and why?

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

1 reference

https://api.crossref.org/works/10.1177%2F0091270009336735

21 January 2018

Identifiers

10.1177/0091270009336735

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19491335

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45985296&oldid=1233512806"